Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)
ID: 337303Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/337303

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-037.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)" aimed at enhancing the understanding of substance use behaviors and related disorders through innovative analyses of existing datasets. This initiative encourages applicants to utilize social science, behavioral, administrative, and neuroimaging data to explore the etiology of drug use, health service utilization, and the impact of environmental factors, without the need for new data collection. With a funding commitment of up to $2 million and a maximum project duration of five years, applications must adhere to NIH guidelines and ethical standards in research involving human subjects. Interested applicants can find more information and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with a submission deadline of November 15, 2024.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    RFA-DA-22-037-Full-Announcement.html
    RFA-DA-22-037.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA), issued a funding opportunity titled "Accelerating the Pace of Drug Abuse Research Using Existing Data" (R01 Clinical Trial Optional). This initiative invites applications for innovative analyses of existing social science, behavioral, administrative, and neuroimaging data to enhance understanding of substance use behaviors and related disorders. The primary objective is to utilize existing datasets, such as the Adolescent Brain Cognitive Development (ABCD) study, to address various research topics without collecting new primary data. Key areas of research focus include the etiology of substance use, health service utilization, and the interaction of environmental factors. Applicants are encouraged to develop novel analytical methods and engage in collaborations to explore diverse datasets, with a maximum project duration of five years and a funding commitment of $2 million. Applications are subject to rigorous review and must adhere to NIH guidelines, ensuring compliance with submission requirements and ethical standards in research involving human subjects. The funding opportunity reflects a broader governmental interest in understanding and combating substance use disorders through data-driven research.
    Similar Opportunities
    Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Accelerating the Pace of Drug Abuse Research Using Existing Data" (RFA-DA-24-037), aimed at enhancing the understanding of substance use behaviors and related disorders through innovative analysis of existing datasets. This initiative specifically seeks applications that utilize previously collected social science, behavioral, and neuroimaging data to investigate the etiology and epidemiology of drug use, prevention strategies, and health service utilization, with a focus on leveraging datasets such as the Adolescent Brain Cognitive Development (ABCD) study. The NIH plans to allocate approximately $2 million annually from FY2023 to FY2025, funding 4-6 grants each year, with a maximum budget of $275,000 for two-year projects. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with proposals due by November 15, 2024.
    Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Mechanism for Time-Sensitive Drug Abuse Research," aimed at supporting urgent exploratory research in substance use epidemiology and health services. This funding initiative focuses on five priority areas, including responses to sudden spikes in drug use, emerging marijuana trends, and time-sensitive issues related to prescription drug abuse and addiction services within the evolving healthcare system. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and state or local governments, with funding available up to $275,000 over a two-year period. Interested parties should note that the application deadline is January 14, 2025, and are encouraged to consult with NIH contacts for alignment with the FOA’s priorities. For further details, applicants can refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-027.html or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R43/R44 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R43/R44 - Clinical Trial Optional)" aimed at supporting Small Business Innovation Research (SBIR) proposals. This initiative seeks innovative, accessible, and affordable solutions to address health complications arising from non-disordered drug use, including issues such as hypoxia-related brain injuries from opioid overdoses and cardiovascular problems from stimulant use. The program anticipates a total budget of $2 million for approximately 2-5 awards in Fiscal Year 2025, with applications due by December 2, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Integrated Functional Mapping and Molecular Profiling of Cell Ensembles Encoding the Effects of Addictive Substances in Rodents (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Integrated Functional Mapping and Molecular Profiling of Cell Ensembles Encoding the Effects of Addictive Substances in Rodents." This initiative aims to support innovative research that utilizes scalable technologies to investigate the cellular responses associated with substance use disorders in rodent models, focusing on integrating neural activity metrics with molecular profiles to enhance understanding of addiction-related neurobehavioral processes. The total funding available is $2 million, with individual grants not exceeding $700,000 in direct costs per year for a project period of up to five years, and proposals must adhere to NIH’s data sharing policies. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with the application deadline set for February 23, 2026.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders" (R61/R33), aimed at supporting innovative clinical research that explores the neurobiological mechanisms underlying substance use disorders (SUD). This initiative encourages applications that investigate neural circuitry and cognitive processes affecting substance use behavior, particularly in the context of the ongoing public health crisis related to SUDs, including the opioid epidemic. The R61/R33 mechanism allows for up to five years of funding, divided into an initial two-year R61 phase and a potential three-year R33 phase, contingent upon meeting specified milestones. Interested applicants can find more information and submit proposals by the application due date of March 13, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for exploratory clinical neuroscience research focused on substance use disorders (SUD) through the R61/R33 phased innovation award mechanism. This funding opportunity aims to support clinical research proposals that investigate the neurobiological mechanisms underlying SUD, allowing for up to five years of funding, with the R61 phase dedicated to initial concept testing and the R33 phase contingent upon achieving specific milestones. The initiative is crucial for advancing understanding of substance abuse impacts in the U.S., encouraging innovative research on topics such as neural circuitry and cognitive factors influencing addiction. Interested applicants, including various educational and nonprofit institutions, can find more details and submit applications by the closing date of May 7, 2026, with no cost-sharing requirement. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-158.html.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)" aimed at advancing clinical research in the field of substance use disorders (SUD). The primary objective is to identify and validate novel targets for non-invasive brain stimulation (NIBS) and to explore the neurobiological, cognitive, and behavioral responses associated with NIBS that may lead to improved clinical outcomes such as reduced cravings or drug use. This initiative is crucial for enhancing understanding and treatment options for SUD through innovative research methodologies. Funding of up to $1.5 million is available for selected projects over a maximum project period of five years, with applications due by August 14, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application instructions available at the provided link.
    Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)," aimed at advancing translational research in the field of substance use. This initiative encourages researchers to engage in a two-phase research process, starting with an R61 planning phase lasting up to two years, followed by an R33 phase for larger studies that may extend up to four years, contingent upon meeting specific milestones. The program emphasizes the importance of community stakeholder engagement and mandates a Plan for Enhancing Diverse Perspectives (PEDP) in all proposals to ensure inclusivity in research development. Interested applicants can find more information and submit their proposals by December 14, 2026, and should direct inquiries to grantsinfo@nih.gov.
    Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)." This initiative aims to support Small Business Technology Transfer (STTR) grant applications focused on developing innovative and accessible solutions to improve health outcomes for individuals affected by non-disordered drug use. The program emphasizes the creation of affordable interventions that can be implemented in community-based care systems, targeting vulnerable populations with limited access to traditional healthcare services. Funding amounts of up to $400,000 for Phase I and $3 million for Phase II are available, with applications due by December 3, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.